Clinical trials: Dense Breasts
Breast Cancer
Automated Breast Ultrasound Screening
Women with dense breasts (BIRADS 3 or 4) with a BIRADS category 1 or 2 mammogram are asked to participate in a automated volume breast ultrasound scanner.
- Trial name
- ABUS (NCT02650778)
- Testing
- Breast ultrasound
- Volunteers
- 2,257 people, healthy volunteers welcome
- Sponsor
- Northeastern Ohio Radiology Research and Education Fund
Breast Cancer
Non-contrast DWI for Supplemental Screening
Diffusion-weighted imaging (DWI) is a short (under 5 minutes) non-contrast MRI technique that has shown promise for the detection and characterization of breast cancer.
- Trial name
- NCT03607552
- Testing
- Non-contrast DWI, Non-contrast MRI
- Where
- 2 sites in United States
- Volunteers
- 269 people
- Sponsor
- University of Washington
Breast Cancer
Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of doxorubicin and docetaxel followed by surgery in…
- Trial name
- NCT00003953
- Testing
- filgrastim, CMF regimen, docetaxel
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Case Comprehensive Cancer Center
Dense Breasts, Breast Cancer
Histology of Functional Density in Postmenopausal Breast
Increased mammographic density is recognized as an important risk factor for developing breast cancer, however, the underlying mechanism explaining this relationship is unclear.
- Trial name
- NCT01240278
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Breast Diseases, Artificial Intelligence
Diagnosis Predictive Modle for Dense Density Breast Tissue Based on Radiomics
It is a prospective, observational cohort study of patients with dense breast tissue. The study was based on the radiomics and other clinicopathological information of patients to establish the diagnostic system for breast…
- Conditions
- Breast Diseases, Artificial Intelligence, Dense Breast Density, Predictive Cancer Model
- Trial name
- NCT04535466
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer
Anthracycline-containing regimens are recommended as adjuvant treatment for women with node positive breast cancer. In at least three large randomized clinical trials the addition or sequential administration of a taxane…
- Trial name
- NCT00431080
- Testing
- Docetaxel, Paclitaxel, Epirubicin
- Where
- 10 sites in Greece
- Volunteers
- 478 people
- Sponsor
- Hellenic Oncology Research Group
Breast Cancer
Supplemental Screening for Women With Extremely Dense Breast Tissue: the DENSE-2 Trial
Women with extremely dense breasts (nearly all glandular and connective tissue, little fatty tissue) have a 3-6 times higher risk of breast cancer than women with very low breast density.
- Trial name
- DENSE-2 (NCT06636370)
- Testing
- Contrast-enhanced mammography (CEM), Abbreviated MRI (AB-MRI)
- Where
- Netherlands
- Volunteers
- 36,000 people, healthy volunteers welcome
- Sponsor
- C.H. van Gils
Breast Cancer, Cancer of Breast
MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
In patients with locally advanced hormone receptor positive (HR+)/HER2- breast cancer, neoadjuvant chemotherapy produces a pathologic complete response rate (pCR) of only 9-15%, and late recurrences often occur despite…
- Trial name
- NCT03285607
- Testing
- MCS110, Doxorubicin, Cyclophosphamide
- Sponsor
- Washington University School of Medicine
Breast Cancer
Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer
This study will determine if docetaxel will be administered before or after doxorubicin/cyclophosphamides in an adjuvant chemotherapy regimen to be evaluated in a subsequent phase III trial.
- Trial name
- NCT00201708
- Testing
- Docetaxel, Doxorubicin, Cyclophosphamide (AC)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
Contrast-enhanced Mammography in Women With a Personal History of Breast Cancer and Dense Breast Tissue: Benefit?
This study aims to assess the effectiveness of Contrast-Enhanced Mammography (CEM)as an alternative to traditional ultrasound for breast cancer screening in women with dense breasts and a personal history of breast cancer.
- Trial name
- CEM (NCT06993246)
- Testing
- Contrast-Enhanced Mammography (CEM)
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Jean Seely
Breast Neoplasms
MBI and Breast Tomosynthesis Screening Accuracies in Patients With Dense Breast Tissue
Primary: In women with heterogeneous or dense breast tissue (mammographic types 3 and 4), MBI (Molecular Breast Imaging) will detect more breast cancers and have greater sensitivity in detecting breast cancer than breast…
- Trial name
- NCT02013726
- Testing
- MBI Scan: The LumaGEM®, 3D Mammogram/Breast Tomosynthesis Scan: Selenia® Dimensions®
- Volunteers
- healthy volunteers welcome
- Sponsor
- Gamma Medica, Inc.
Breast Cancer, Adenocarcinoma of the Breast
Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility
The purpose of this study is to give a drug regimen that is hoped to be effective in preventing cancer from coming back. Since it is an aggressive breast cancer, there is a moderate to high chance that the cancer may come back.
- Trial name
- NCT00617370
- Testing
- epirubicin, cyclophosphamide, Paclitaxel,
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Gastrointestinal Cancer
Capecitabine in Metastatic Breast and GI Cancers
The purpose of this study is compare different doses of capecitabine to see if one is better than the other in terms of efficacy and toxicity.
- Trial name
- X7-7 (NCT02595320)
- Testing
- Capecitabine
- Where
- 15 sites in United States
- Volunteers
- 200 people
- Sponsor
- Qamar Khan
Triple Negative Breast Cancer
The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency
The purpose of this trial is to compare the 3-year disease-free survival of dose-dense epirubicin and cyclophosphamide followed by paclitaxel with paclitaxel plus carboplatin as adjuvant therapy for triple-negative breast cancer…
- Trial name
- NCT03876886
- Testing
- Epirubicin, Cyclophosphamide, Paclitaxel
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese Academy of Medical Sciences
Breast Cancer Detection, Breast Neoplasm
Molecular Breast Imaging (MBI)-Guided Biopsy
The goal of this pilot clinical trial is to demonstrate supplemental screening MBI (molecular breast imaging) in women with dense breasts.
- Conditions
- Breast Cancer Detection, Breast Neoplasm, Molecular Imaging, Biopsy
- Trial name
- MBI-GB-Pilot (NCT07114679)
- Testing
- Molecular Breast Imaging, MBI-guided biopsy
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Smart Breast Corp.
Breast Cancer
Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer
The rationale of this randomized phase II study is to investigate the feasibility of sequenced densified FEC and docetaxel based regimens in patients with primary operable high-risk breast cancer.
- Trial name
- NCT00256360
- Testing
- dose dense with neulasta
- Where
- Belgium
- Volunteers
- 117 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Node Positive Breast Cancer
Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer
To screen a dose-dense arm to be used in a future large scale phase III trial. Primary endpoint is safety; secondary endpoints are disease free survival and overall survival. A total of 100 patients were included.
- Trial name
- NCT00189670
- Testing
- 6 TEC q 3 weeks, 4 EC q 2 weeks followed by 4 TXT q 2 weeks, 4 TXT q 2 weeks followed by 4 EC q 2 weeks
- Sponsor
- Association Européenne de Recherche en Oncologie
Dense Breasts
RANKL Inhibition and Mammographic Breast Density
Data supporting a role for RANKL signaling in mammographic density and breast cancer development has begun to emerge, but clinical trial data providing definitive evidence that would allow the adoption of RANKL inhibition in…
- Trial name
- TRIDENT (NCT04067726)
- Testing
- Denosumab, Calcium, Vitamin D3
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Washington University School of Medicine
Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
This randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery.
- Conditions
- Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
- Trial name
- NCT00861705
- Testing
- Bevacizumab, Carboplatin, Cyclophosphamide
- Where
- 448 sites in United States
- Volunteers
- 454 people
- Sponsor
- National Cancer Institute (NCI)
HER2-negative Breast Cancer, Neoadjuvant Chemotherapy
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
Recent clinical studies showed that breast cancer patients especially for those with lymph node metastasis may benefit from dose-dense chemotherapy, like adriamycin and cyclophosphamide (AC) q2w×4→ paclitaxel (P) q2w×4.
- Trial name
- NCT04576143
- Testing
- Epirubicin, Cyclophosphamid, Docetaxel
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine